Skip to content

A single-center parallel-controlled study of combined hydroxide inhalation to improve side effects of postoperative radiotherapy for breast cancer

A single-center parallel-controlled study of combined hydroxide inhalation to improve side effects of postoperative radiotherapy for breast cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092092
Enrollment
Unknown
Registered
2024-11-08
Start date
2023-03-13
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

hydrogen-absorbing group:The hydrogen treatment group inhaled hydrogen for 1 hour befor and after radiotherapy and inhaled it continuously during radiotherapy.
control group :None

Sponsors

Tai'an City Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age between 18-75 years old. (2) Pathologic examination results were determined to be breast cancer. (3) All patients underwent surgical treatment for breast cancer. (4) Clear consciousness and good compliance.

Exclusion criteria

Exclusion criteria: (1) Diagnosed with other types of malignant tumors before the first administration of the drug. (2) Combined severe cardiopulmonary insufficiency. (3) Those who are allergic to the drugs taken during treatment.

Design outcomes

Primary

MeasureTime frame
metabolites;

Secondary

MeasureTime frame
imflammatory factor;lymphocyte subset;oxidative stress;

Countries

China

Contacts

Public ContactYujiao Sun

Tai'an City Central Hospital

anniesyj@163.com+86 191 5386 2711

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026